Surgery-Induced Cancer Metastasis - Part 5

Conclusion
The purpose of posting these articles are of two fold:

1) Preventing Surgery Induced Metastasis
- A patient undergoing surgery, especially cancer patient must be aware of the risks involved in tumor removal. While the surgery can debulk much or most of the tumors to ease the burden on the body, at the same time, the surgery can cause the tumor to spread to other sites.
- Patients undergoing biopsy will also be exposed to the same risks.
- There are certain preoperative medication and supplements that a patient can take five days prior to the surgery to prevent surgery induced metastasis.

2) Preventing Metastasis In Cancer Patients
We now know that cancer does spread, namely a) from the primary site when the tumors reached a certain size, b) during surgery and c) during biopsy.

So whether a cancer person goes for surgery or not, it's a matter of time the cancer spread to other sites and when that happen, the patient is deemed to have reached stage 4. What these articles have shown is why must we wait to take medication and supplements just before operation to prevent the spreading? For stage 2 and 3 cancer patients, where the spreading has yet to occur, why don't these patients take those medication and supplement to prevent spreading while undergoing whatever treatments? More importantly for stage 4 cancer patients, why not also take the medication and supplement to prevent further spreading?

Like me, my tumors have already spread from my right kidney to my lungs. The natural progression is that it will continue to spread to the bones, liver and then the brain. So what I can do now is to start to take those medication and supplement to prevent further spreading.

Perhaps because I am not a doctor, my recommendation may seem bold but are based on research and clinical trials. It could prolong the cancer patient's life while in treatment and hopefully recovery and at the same time have a better quality of life. This is something for cancer patients to consider. You can read the full article here.

TABLE 1 - Modified Citrus Pectin (MCP) Dosage

MCP Application	Use (take on an empty stomach)
Active Cancer	15 grams/day (5 grams three times a day)
Biopsy	15 grams/day (5 grams three times a day). Take one week before procedure and two weeks after.
Heavy Metal Chelation	High body burden levels: 15 grams/day (5 grams three times a day). Lower body burden levels: 15 grams/day for 5 days a month, 5 grams/day the rest of the month

What You Need to Know: Modified Citrus Pectin

Pectin is a complex carbohydrate that is abundantly present in citrus fruits. Modified citrus pectin (MCP) is composed of short, non-branched carbohydrate chains derived from the peel and pulp of citrus fruits. Compelling research suggests that modified citrus pectin may help block the growth and metastasis of solid tumors such as breast, colon, and prostate cancers. Intriguing clinical studies suggest that supplementation with MCP stabilizes disease progression and lengthens PSA doubling times in men with prostate cancer. Modified citrus pectin may represent a safe, non-toxic d of chelating toxic metals without the need for intravenous infusions. Supplementation with MCP has been shown to increase excretion of dangerous metals such as mercury, arsenic, lead, and cadmium—without removing essential minerals like calcium, magnesium, and zinc from the body. A clinical study showed that supplementation with an MCP-alginate complex reduced total body toxic heavy metal burden in patients with a variety of health concerns. MCP is considered safe and well tolerated. Dosages range from 6 to 30 grams per day in divided dosages; a typical dose is 5 grams three times daily.

TABLE 2 - Cimetidine (commonly known as Tagamet®) Dosage

Application	Use (take on an empty stomach)
Active Cancer	800 mg of cimetidine daily (400 mg twice daily)

Cimetidine: What You Need to Know

Cimetidine is an over-the-counter, acid-blocking drug originally developed to treat heartburn, upset stomach, ulcers, and gastroesophageal reflux disease. In the 1980s, scientists noted that cancer patients who received cimetidine to manage chemotherapy-associated nausea experienced better outcomes, which led them to further investigate cimetidine cancer-fighting effects. In 1985, Life Extension first called attention to cimetidine promise as a novel anti-cancer therapy. Since then, more than 20 years of research has documented cimetidine cancer-fighting effects. Used in conjunction with other cancer therapies, cimetidine has been found to significantly enhance cancer survival rates. Cimetidine works through several mechanisms of action, preventing immune suppression caused by tumor secretion of histamine, halting cancer growth, preventing angiogenesis, promoting cancer cell death, and averting often-fatal cancer metastasis. Further studies are needed to assess cimetidine cancer-fighting abilities as both a sole therapeutic and an adjuvant cancer remedy.